Abbott Laboratories (ABT) Set to Release Earnings on Wednesday

Abbott Laboratories (NYSE:ABT) is projected to issue its Q3 2026 results before the market opens on Wednesday, October 21st. Analysts expect Abbott Laboratories to announce earnings of $1.42 per share and revenue of $12.99 billion for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 21, 2026 at 9:00 AM ET.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter last year, the company posted $1.26 earnings per share. The company’s revenue for the quarter was up 13.0% compared to the same quarter last year. On average, analysts expect Abbott Laboratories to post $5.52 EPS for the current fiscal year and $6.08 EPS for the next fiscal year.

Abbott Laboratories Stock Performance

Shares of ABT opened at $104.79 on Monday. The firm has a 50-day moving average of $105.91 and a 200-day moving average of $98.29. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02. The company has a market cap of $181.33 billion, a PE ratio of 33.91, a price-to-earnings-growth ratio of 1.94 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ABT shares. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price for the company in a research note on Thursday, August 13th. Rothschild & Co Redburn raised Abbott Laboratories from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $119.00 to $127.00 in a research report on Friday, October 2nd. JPMorgan Chase & Co. upped their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. BTIG Research upped their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Finally, Barclays assumed coverage on Abbott Laboratories in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $118.88.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.